Symbiotec Pharmalab Ltd (SYMBIOTEC)
NSE · Healthcare · Pharmaceuticals & Biotechnology · Pharmaceuticals
₹1,246.30
As of 30 Oct 2026 close.
Facts from reported results and exchange filings. Not investment advice.
Share price
Prices load here as you scroll to them.
Last close ₹1,246.30 on 30 Oct 2026. The share price traded between ₹934.20 and ₹1,309.90 (intraday) since listing on 1 Sep 2026.
The closes as a table
| Date | Close |
|---|
Key figures
Range since listing on 1 Sep 2026 (intraday)
Low ₹934.20High ₹1,309.90
Price trend
- Supertrend (10, 3): the price has closed below the line for 41 trading days.
Revenue and profit
| Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 682 | 567 | 716 | 752 | 869 |
| Net profit | 78 | 23 | 100 | 97 | 110 |
| EBITDA margin | 19% | 12% | 24% | 27% | 27% |
| Borrowings | 65 | 218 | 247 | 544 | 391 |
₹ crore. Over three years, compounded: revenue grew 15.3% a year, net profit grew 68.5% a year.
Recent filings
- 30 Sep 2026
Symbiotec's wholly owned subsidiary Knovea Pharmaceutical enters into strategiccommercialization agreement… - 29 Sep 2026
Announcement Under Regulation 30 (LODR)-Symbiotec Pharmalab Limited Receives Establishment Inspection Report… - 28 Sep 2026
Earnings call: Analysts/Institutional Investor Meet/Con. Call Updates - 22 Sep 2026
Earnings call: Analysts/Institutional Investor Meet/Con. Call Updates - 21 Sep 2026
Financial results: Press Release - 21 Sep 2026
Investor presentation
Questions about Symbiotec Pharmalab Ltd
What is Symbiotec Pharmalab Ltd's market value?
Symbiotec Pharmalab Ltd's market value is ₹8,006 crore as of 30 Oct 2026 close: the last close times the shares in issue. Its P/E is 71.1, the last close over earnings per share for the last four reported quarters.
When are Symbiotec Pharmalab Ltd's next results?
Symbiotec Pharmalab Ltd's next results are listed for 5 Nov 2026 (the exchange's notice: Financial Results). Dates are as the company announced them, on the list of 30 Oct 2026.
Who are Symbiotec Pharmalab Ltd's largest named shareholders?
In the shareholding pattern for the quarter ended 30 Sep 2026, the largest named holders above 1% were: Satwani Holdings LLP (promoter group) 15.28%; Rosewood Investments (public) 14.07%; Anil Satwani (promoter group) 11.75%. Percentages are of all shares.
Go further with SYMBIOTEC
Free to start: test a trading idea on SYMBIOTEC's real prices after costs, or open the full deep dive with ten years of numbers, red flags and management's record.
Same industry
The largest companies in the same industry (Pharmaceuticals), by market value.
Browse companies
The companies before and after this one, A to Z, and the lists it is in.
How these figures are worked out
- Last close: the closing price on the date shown. The page follows the market's close; it doesn't show prices during the session. A price older than the market's latest close, or a last trade that isn't a close, is labelled as the last price, with the session it is from.
- 1-year range: the lowest and highest prices traded during the sessions of the last year (intraday), so they can lie outside the closing prices.
- Market cap: the last close times the shares in issue. It is n/a when it doesn't agree with the company's own reported figures (for example a depositary share counted as an ordinary share).
- P/E: the last close divided by earnings per share over the last four reported quarters, the profit that belongs to the company's shareholders per share, as the company reports it. So P/E can differ from market cap divided by the net profit shown (a different share count, or the profit before minority interests; where they differ by more than 10%, a note under the figures gives both). A company that reports only once a year has its latest year's earnings, and the P/E names that year; when that year ended more than about 15 months before the close, P/E is n/a. A loss has no P/E. Above 1,000 it is n/a.
- EBITDA margin: operating profit before depreciation, interest and tax (and before other income), as a share of revenue in the latest reported year, the table's last column. The results give it in whole percent.
- Net margin: net profit as a share of revenue in the latest reported period. Return on equity, the margins and debt to equity each use inputs from that one year; if one input is missing for it, the figure is n/a. When that year ended more than about 15 months before the close, they are n/a too.
- Dividend yield: every dividend per share with an ex-date in the 12 months to the last close, special dividends included, as a share of that close. n/a when the company's dividends couldn't be read.
- n/m: not meaningful. A margin or return beyond ±1,000% comes from revenue or equity near zero, so it is not shown as a number.